DRNA - Watch for Continued Gains in Shares of Dicerna Pharmaceuticals Inc. (DRNA)

Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded at a new 52-week high today of $38.01. This new high was reached on below average trading volume as 124,000 shares traded hands, while the average 30-day volume is approximately 724,000 shares.

Dicerna Pharmaceuticals Inc is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. The company is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are nedosiran (for primary hyperoxaluria), belcesiran (for genetic liver disease), DCR-PCSK9 (for cardiovascular disease), and RG6346 (for hepatitis B virus) among others.

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) defies analysts with a current price ($37.89) 6.1% above its average consensus price target of $35.57.

In the past 52 weeks, shares of Dicerna Pharmaceuticals Inc. have traded between a low of $16.50 and a high of $38.01 and is now at $37.89, which is 130% above that low price.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer